Aileron Therapeutics, Inc. (NASDAQ:ALRN) Sees Large Growth in Short Interest

Aileron Therapeutics, Inc. (NASDAQ:ALRN) saw a large growth in short interest in April. As of April 15th, there was short interest totalling 43,400 shares, a growth of 22.9% from the March 31st total of 35,300 shares. Currently, 0.3% of the company’s stock are sold short. Based on an average trading volume of 65,900 shares, the short-interest ratio is presently 0.7 days.

Aileron Therapeutics Price Performance

Shares of ALRN stock opened at $5.00 on Monday. The firm has a 50 day moving average price of $5.42 and a two-hundred day moving average price of $3.75. The company has a market capitalization of $84.87 million, a PE ratio of -1.48 and a beta of 2.22. Aileron Therapeutics has a 12-month low of $1.01 and a 12-month high of $7.42.

Aileron Therapeutics (NASDAQ:ALRN) last issued its quarterly earnings data on Monday, April 15th. The company reported ($1.54) earnings per share (EPS) for the quarter. As a group, research analysts expect that Aileron Therapeutics will post -0.62 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, LADENBURG THALM/SH SH raised their target price on shares of Aileron Therapeutics from $9.00 to $19.00 and gave the company a “buy” rating in a research note on Thursday, April 18th.

Institutional Investors Weigh In On Aileron Therapeutics

An institutional investor recently bought a new position in Aileron Therapeutics stock. Sigma Planning Corp purchased a new stake in Aileron Therapeutics, Inc. (NASDAQ:ALRN) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 16,580 shares of the company’s stock, valued at approximately $51,000. Sigma Planning Corp owned approximately 0.34% of Aileron Therapeutics at the end of the most recent quarter. 90.89% of the stock is currently owned by hedge funds and other institutional investors.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial.